Article information
Full text is only available in PDF
General references
[Accorinti et al., 2007]
M. Accorinti, M.P. Pirraglia, M.P. Paroli, R. Priori, F. Conti, P. Pivetti-Pezzi.
Infliximab treatment for ocular and extraocular manifestations of Behcet's disease.
Jpn J Ophthalmol, 51 (2007), pp. 191-196
[Bartolucci et al., 2002]
P. Bartolucci, J. Ramanoelina, P. Cohen, A. Mahr, P. Godmer, C. Le Hello, et al.
Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients.
Rheumatology (Oxford), 41 (2002), pp. 1126-1132
[Brihaye et al., 2007]
B. Brihaye, A. Aouba, C. Pagnoux, P. Cohen, F. Lacassin, L. Guillevin.
Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients.
Clin Exp Rheumatol, 25 (2007), pp. S23-S27
[Cavagna et al., 2001]
L. Cavagna, R. Caporali, O. Epis, F. Bobbio-Pallavicini, C. Montecucco.
Infliximab in the treatment of adult Still's disease refractory to conventional therapy.
Clin Exp Rheumatol, 19 (2001), pp. 329-332
[Chiappetta et al., 2005]
N. Chiappetta, J. Steier, B. Gruber.
Rituximab in the treatment of refractory dermatomyositis.
J Clin Rheumatol, 11 (2005), pp. 264-266
[Connolly et al., 2005]
M. Connolly, J.S. Armstrong, D.A. Buckley.
Infliximab treatment for severe orogenital ulceration in Behcet's disease.
Br J Dermatol, 153 (2005), pp. 1073-1075
[Erdozain et al., 2004]
J.G. Erdozain, G. Ruiz-Irastorza, M.V. Egurbide, C. Aguirre.
Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome.
Haematologica, 89 (2004), pp. ECR34
[Eriksson, 2005]
P. Eriksson.
Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab.
J Intern Med, 257 (2005), pp. 540-548
[Fautrel et al., 2005]
B. Fautrel, J. Sibilia, X. Mariette, B. Combe.
Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases.
Ann Rheum Dis, 64 (2005), pp. 262-266
[Fra et al., 2003]
G.P. Fra, G.C. Avanzi, E. Bartoli.
Remission of refractory lupus nephritis with a protocol including rituximab.
Lupus, 12 (2003), pp. 783-787
[Gottenberg et al., 2005]
J.E. Gottenberg, L. Guillevin, O. Lambotte, B. Combe, Y. Allanore, A. Cantagrel, et al.
Club Rheumatismes et Inflammation (CRI). Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
Ann Rheum Dis, 64 (2005), pp. 913-920
[Johnston, 2007]
S.L. Johnston.
Biologic therapies: what and when?.
J Clin Pathol, 60 (2007), pp. 8-17
[Jonsdottir et al., 2008]
T. Jonsdottir, I. Gunnarsson, A. Risselada, E. Welin Henriksson, L. Klareskog, R.F. Van Vollenhoven.
Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response.
Ann Rheum Dis, 67 (2008), pp. 330-334
[Koukoulaki et al., 2006]
M. Koukoulaki, K.G. Smith, D.R. Jayne.
Rituximab in Churg-Strauss syndrome.
Ann Rheum Dis, 65 (2006), pp. 557-559
[Leandro et al., 2005]
M.J. Leandro, G. Cambridge, J.C. Edwards, M.R. Ehrenstein, D.A. Isenberg.
B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.
Rheumatology (Oxford), 44 (2005), pp. 1542-1545
[Mok et al., 2007]
C.C. Mok, L.Y. Ho, C.H. To.
Rituximab for refractory polymyositis: an open-label prospective study.
J Rheumatol, 34 (2007), pp. 1864-1868
[Ramos-Casals et al., 2007]
M. Ramos-Casals, P. Brito-Zeron, S. Muñoz, N. Soria, D. Galiana, L. Bertolaccini, et al.
Autoimmune diseases induced by TNFtargeted therapies: analysis of 233 cases.
Medicine (Baltimore), 86 (2007), pp. 242-251
[Sfikakis et al., 2005]
P.P. Sfikakis, J.N. Boletis, G.C. Tsokos.
Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.
Curr Opin Rheumatol, 17 (2005), pp. 550-557
[Sibilia, 2006]
J. Sibilia.
Biological therapies: evolution or revolution?.
Presse Med, 35 (2006), pp. 637-640
[Stasi et al., 2006]
R. Stasi, E. Stipa, G. del Poeta, S. Amadori, A.C. Newland, D. Provan.
Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
Rheumatology (Oxford), 45 (2006), pp. 1432-1436
[Tokunaga et al., 2005]
M. Tokunaga, K. Fujii, K. Saito, S. Nakayamada, S. Tsujimura, M. Nawata, et al.
Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.
Rheumatology (Oxford), 44 (2005), pp. 176-182
[Wegener's, 2005]
Wegener's Granulomatosis Etanercept Trial (WGET) Research Group.
Etanercept plus standard therapy for Wegener's granulomatosis.
N Engl J Med, 352 (2005), pp. 351-361
On behalf of the Grupo de Enfermedades Autoinmunes Sistémicas (GEAS [working group for systemic autoimmune diseases]), which is part of the Sociedad Española de Medicina Interna (SEMI [Spanish Internal medicine society]) and the GEAS biological therapies register (BIOGEAS register)
Copyright © 2009. Sociedad Española de Farmacia Hospitalaria
